Reversible delayed onset olanzapine-associated leukopenia and neutropenia in a clozapine-naive patient on concomitant depot antipsychotic [2]

Journal of Clinical Psychopharmacology

Volumn 27, Issue 4, 2007, Pages 394-395

  Thinn, San San ^a   Liew, Emily ^a   May, Athi Lachai ^a   Chua, Hong Choon ^a   Sim, Kang ^a  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; OLANZAPINE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL DECANOATE;

ADULT; CASE REPORT; DRUG DOSE INCREASE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; LETTER; LEUKOCYTE COUNT; LEUKOPENIA; NEUTROPENIA; PATIENT MONITORING; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; LEUKOPENIA; MIDDLE AGED; NEUTROPENIA; SCHIZOPHRENIA;

EID: 34447528938     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000264987.70850.6a     Document Type: Letter

References (18)

1. Dettling M, Cascorbi I, Hellweg R, et al. Genetic determinants of drug-induced agranulocytosis: potential risk of olanzapine? Pharmacopsychiatry. 1999;32:110-112.
2. Stubner S, Grohmann R, Engel R, et al. Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry. 2004;37:S70-S78.
3. Tolosa-Vilella C, Ruiz-Ripoll A, Mari-Alfonso B, et al. Olanzapine-induced agranulocytosis: a case report and review of the literature. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:411-414.
4. Benedetti F, Cavallaro R, Smeraldi E. Olanzapine-induced neutropenia after clozapine-induced neutropenia. Lancet. 1999;354 (9178):567.
5. Thangadurai P, Jyothi KS, Gopalakrishnan R, et al. Reversible neutropenia with olanzapine following clozapine-induced neutropenia. Am J Psychiatry. 2006;163:1298.
6. Abdullah N, Voronovitch L, Taylor S, et al. Olanzapine and haloperidol: potential for neutropenia? Psychosomatics. 2003;44:83-84.
7. Duggal HS, Gates C, Pathak PC. Olanzapine-induced neutropenia: mechanismand treatment. J Clin Psychopharmacol. 2004;24:234-235.
8. Hirshberg B,GuralA, CaracoY. Zuclopenthixol-associated neutropenia and thrombocytopenia. Ann Pharmacother. 2000;34:740-742.
9. Esposito D, Corruble E, Hardy P, et al. Risperidone-induced morning pseudoneutropenia. Am J Psychiatry. 2005;162:397.
10. Montgomery J. Ziprasidone-related agranulocytosis following olanzapine-induced neutropenia. Gen Hosp Psychiatry. 2006;28:83-85.
11. Pessina A, Turlizzi E, Bonomi A, et al. In vitro toxicity of clozapine, olanzapine, and quetiapine on granulocyte-macrophage progenitors (GM-CFU). Pharmacopsychiatry. 2006;39:20-22.
12. Schuld A, Kraus T, Hinze-Selch D, et al. Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia. Acta Psychiatr Scand. 2000;102:153-155.
13. Guest I, Uetrecht J. Drugs that induce neutropenia/agranulocytosis may target specific components of the stromal cell extracellular matrix. Med Hypotheses. 1999;53:145-151.
14. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993;329:162-167.
15. Steinwachs A, Grohmann R, Pedrosa F, et al. Two cases of olanzapine-induced reversible neutropenia. Pharmacopsychiatry. 1999;32:154-156.
16. Gardner I, Leeder JS, Chin T, et al. A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and vivo. Mol Pharmacol. 1998;53:999-1008.
17. Gardner I, Zahid N, MacCrimmon D, et al. A comparism of oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leucocytes. Mol Pharmacol. 1998;53:991-998.
18. Kassahun K, Mattiuz E, Franklin R, et al. Olanzapine 10-N- glucuronide. A tertiary N-glucuronide unique to humans. Drug Metab Dispos. 1998;26:848-855.